Table 1.

Patient characteristics and CMV disease/infection after SCT

Patient no	Diagnosis	Patient’s HLA-A	Donor	Donor’s HLA-A	Donor’s CMV serostatus	Conditioning regimen	aGvHD post-SCT	Day of aGvHD post-SCT	Day of aGvHD treatment post-SCT	Day of CMV reactivation post-SCT	CMV reactivation symptom	CMV load upon 1st dose of TCR-T cell	Day of TCR-T cell infusion post-SCT
01	AML	02:01, 02:07	Daughter	02:01, 02:07	Positive	DAC+BU/CY+ATG	Yes	20	Steroids (1 mg/kg, D20–27, 0.5 mg/kg, D28–32) and ruxolitinib (5 mg, D20–32)	37	Viremia	16 520 copies/mL	41, 47
02	MDS-EB2	02:01, 33:03	Sibling	02:01, 33:03	Positive	DAC+BU/CY+ATG	Yes	111	Steroids (1 mg/kg, D111–119, 0.5 mg/kg, D120–125), anti-CD25 monoclonal antibody (D111, 113, 118, 125 and 133) and ruxolitinib (5 mg, D112–127)	118	Colitis	2368 copies/mL	120
03	AML	24:02, 02:01	Son	24:02, 02:01	Positive	DAC+BU/CY+ATG	Yes	17	Steroids (1 mg/kg, D17–21, 0.5 mg/kg, D22–23), anti-CD25 monoclonal antibody (D24, 27 and 32) and ruxolitinib (5 mg, D17–37)	30	Colitis	<1000 copies/mL*	32, 37, 55
04	AML	24:02, 02:06	Father	24:02, 33:03	Positive	DAC+BU/CY+ATG	Yes	30	Steroids (1 mg/kg, D30–35, then 0.5 mg/kg, D36–38), anti-CD25 monoclonal antibody (D31, 33, 38, 45, 53) and ruxolitinib (5 mg, D30–44)	47	Pneumonia	3710 copies/mL	50, 57, 68
05	ALL	02:03, 24:02	Son	02:03, 24:02	Positive	DAC+BU/CY+ATG	No	N/A	N/A	43	Viremia	10 650 copies/mL	61, 65
06	AML	11:01, 02:07	Son	11:01, 11:01	Positive	DAC+BU/CY+ATG	No	N/A	N/A	45	Viremia	1100 copies/mL	45

*Patient 03 developed CMV colitis on day 30 post-SCT, 9 days before blood CMV load reached ≥1×10³ copies/mL. To treat CMV colitis on time, the first dose of CMV-TCR-T cells was infused on day 32 post-SCT. On that day, blood CMV-DNA level was <1000 copies/mL.

aGvHD, acute graft-versus-host disease; ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; ATG, anti-thymocyte globulin; BU, busulfan; CMV, cytomegalovirus; CY, cyclophosphamide; DAC, decitabine; HLA, human leukocyte antigen; MDS-EB2, myelodysplastic syndromes with excess blasts type 2;N/A, not applicable; SCT, stem cell transplantation; TCR-T cell, T cell receptor-engineered T cell;